

2 December 2016

Omni Innovation Market Update

Highlights

- Omni Innovation's flagship product, Faulding® GlucoControl™ is currently in over 1,000 pharmacies across Australia under license agreement with Endeavour Consumer Health using its Symbion network.
- Adelaide University released a ground-breaking study in September 2016 at the European Association for the Study of Diabetes confirming that Faulding® GlucoControl™ can significantly reduce the dangerous blood sugar spikes after a standard meal and improve overall glycaemic control (HbA1c) in the long term.
- Omni Innovation has entered into an offshore agreement with Healthspan, the **UK's** number one direct supplier of vitamins and supplements through a binding exclusive product license term sheet. Market release is planned for April 2017.
- Omni Innovation has begun registration of its export product GlucoSmooth™ into **Malaysia**. Through a representation agreement with US Company Global Brand Consulting LLC negotiations are advancing with key distribution partners in the **US and China**. Distribution partners are also shortlisted in **Scandinavia and China**.
- Distribution arrangements for **Singapore** and later **Hong Kong** are in commercial discussions with a highly-experienced distribution partner.
- In 2016 key independent opinion leaders have presented Faulding® GlucoControl™ Information Sessions for health professionals across Australia. Faulding® GlucoControl™ was featured on the Nine Network's Today Show and in The Australian newspaper.
- A research agreement is in place with Adelaide University for a new product addressing Postprandial Hypotension. A research agreement with Deakin University, Adelaide University and the University of South Australia is progressing a new program that combines GlucoControl™ and behavioural intervention in managing diabetes.
- Mr Philip Owens was appointed as Director of Sales & Marketing, formerly Global Brand Team Leader with pharma multinational Bayer AG.

EVE Investments (ASX: EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical nutrition company focused on non-pharmaceutical, clinically validated early intervention treatments for common chronic diseases.

Distribution

Under Omni Innovation's license agreement with Endeavour Consumer Health using its Symbion network, Faulding® GlucoControl™ a natural, pre-meal drink for the dietary management of people with prediabetes and type 2 diabetes is currently in over 1,000 pharmacies across **Australia**.

Omni Innovation has entered into a binding term sheet for a 15-year exclusive product licence agreement with **UK** company Healthspan, the **UK's** leading direct supplier of vitamins and supplements. Under this agreement, Healthspan will manufacture and brand the product and must achieve milestones and marketing commitments to maintain exclusivity of distribution. Omni Innovation will receive a royalty based off gross sales of the product in the **UK**.

The representation agreement with **US** Company Global Brand Consulting LLC (part of the Star Brands network) has identified several key distribution partners in the US and other regions. A market launch is planned in March/April 2017. Negotiations are advancing with the shortlisted partners.

Omni Innovation's agreement with OHC to seek potential distribution partners across **Scandinavia** has identified and shortlisted several companies.

Discussions with **Chinese** company Beijing Dongfang Hongsheng International Biotechnology Development Co. Ltd to enter a definitive agreement on the registration, marketing and sales in China of Omni Innovation's export product GlucoSmooth™ are progressing. Furthermore, the Company is pursuing commercial discussions with a potential partner in **Singapore** and **Hong Kong**.



Image 1: (left) Faulding® GlucoControl™ packaging in Australia, (right) draft product packaging for the international branding of GlucoSmooth™

In November, Tianjin Tongrentang Group, a company with a long history of pharmaceutical distribution and sales, become a significant shareholder in EVE via a placement. Tianjin Tongrentang has a well-developed, extensive distribution network throughout **China**.

Omni Innovation has begun registration of its export product GlucoSmooth™ into **Malaysia**. Omni Innovation is working with a Malaysian company that specialises in importing and distribution of foods for special medical purposes. The Malaysian party will manage the registration process and commence sales in Malaysia on a non-exclusive basis.

Marketing, Promotion and Product Validation

Omni Innovation continues to hold promotional information sessions across Australia for medical practitioners, pharmacists, dieticians and diabetes educators. These sessions incorporate independent key opinion leaders such as Professor Peter Clifton, Dr Alan Barclay, Professor Jennie Brand Miller ("GI Jennie"), Dr Linda Watson and Dr Tongzhi Wu. Events have been successfully run in Perth, Melbourne, Sydney, Adelaide and Brisbane. Due to the success of educating health care professionals at these events, they will be continued in 2017 in Hobart, Canberra and Darwin in addition to revisiting Australia's major cities.



Image 2: Information session held in Brisbane on 30 November 2016

Diabetes WA, Vic, SA, NSW & QLD have all attended and or participated in Omni Innovation information sessions and positive feedback has been received. Each of the state based Diabetes associations have been engaged to build awareness and receive feedback on Faulding® GlucoControl™.

Interim results from new research conducted by the University of Adelaide announced a new breakthrough in the management of type 2 diabetes – one of the world's fastest growing diseases. The findings were presented at the 2016 European Association for the Study of Diabetes Annual General Meeting in Germany and reveal that Faulding® GlucoControl™ can significantly reduce the dangerous blood sugar spikes after a standard meal and improve overall glycaemic control (HbA1c) in the long term.

Omni Innovation appointed Mr Philip Owens as Director of Sales & Marketing in July 2016. Previously Mr Owens worked for Bayer in Germany where he was global head of its woman's health division and doubled the revenue of this business to over 1.2 billion Euro. Mr Owens joined Omni Innovation on a full-time basis in September 2016.

Faulding launched a TV Commercial marketing campaign for Faulding® GlucoControl™ in late September. Additionally, the product was profiled in an article in The Australian's health section on 19 September 2016 and Dr. Ross Walker presented a segment on the benefits of the product on the Nine Network's Today Show, on 20 September 2016.

Omni Innovation has produced promotional and educational videos with key opinion leaders as well a consumer case study. Videos have also been produced of the information session held in Sydney and Dr Linda Watson presenting the Adelaide University interim results.

Links to the recent media and videos involving Omni Innovation are available through the EVE Investments website, www.eveinvestments.com.au

New Product Development

Progress has been made in the development of a new early intervention product for **Postprandial Hypotension** in the elderly. This product will address drop in blood pressure following a meal. Adelaide University has agreed to carry out research to provide validation for the development of a commercial product. Professor Karen Jones will supervise this study.

The development of a new program managing diabetes using the combination of the pre-meal drink with a behavioural intervention is progressing. A large grant application has been lodged and Deakin University, Adelaide University and the University of South Australia have agreed to participate in the program research.

The development of complimentary products to Faulding® GlucoControl™ for people with type 2 diabetes has commenced. Targeting different methods of consumption, these products aim to suit different segments of the market.

Capital Raising Initiatives

In early November Tianjin Tongrentang Group became a significant shareholder in EVE via a \$600k placement at 1 cent per share. The Company is currently seeking to raise up to an additional \$1,959,167 by a pro-rata non-renounceable rights offer of up to 195,916,687 shares on the basis of 1 new share for every 6 shares held at an issue price of 1 cent per share. The offer opened on 25 November 2016 and closes on 6 December 2016.

The rights issue is not underwritten and Westar Capital Ltd has been appointed as lead manager to place any shortfall in conjunction with the Directors. The Company has already received strong interest from several parties regarding participation in the shortfall.

Funds raised in the capital raisings will be used to complete the settlement of the second tranche investment into Omni Innovation. Upon completion of EVE's investment into Omni Innovation the Company will seek to fast-track the company towards completing an IPO listing. EVE shareholders will receive a priority entitlement to Omni Innovation shares in the IPO process.

About Omni Innovation

Omni Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases.

For more information, please visit www.omniinnovation.com.au

About EVE Investments

EVE Investment is an Australian Securities Exchange Listed Investment Company that assists emerging technology companies further develop and expand by facilitating access to capital and management expertise.

For more information, please visit www.eveinvestments.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au